Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-Immunotherapy
Time schedules and results for tumor volume, survival periods and rates of mice treated by Protocol number 3. (a) Protocols of Groups I, II, III, IV, V, and VI. (b) Tumor volumes on day 14 after re-challenge with B16F1 melanoma. All data are presented as mean ± standard deviation. Tumor volumes of Groups III, IV, and V were significantly reduced compared with the control group , and resp.) by the Scheffé test. (c) Kaplan-Meier survival curve over a period of 60 days after tumor re-challenge. Survival rates of Groups III and IV were significantly prolonged compared with that of the control group ( and , resp.). One of the nine mice in Group III and four of the nine mice in Group IV were protected against re-challenge with B16F1 melanoma cells.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.